FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245709671> ?p ?o ?g. }

• W4245709671 endingPage "1311" @default.
• W4245709671 startingPage "1304" @default.
• W4245709671 abstract "CancerVolume 61, Issue 7 p. 1304-1311 ArticleFree Access Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation First published: 1 April 1988 https://doi.org/10.1002/1097-0142(19880401)61:7<1304::AID-CNCR2820610705>3.0.CO;2-ICitations: 33AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract From January 1978 to May 1983, 41 patients with primary high-grade osteogenic osteosarcoma of a limb were treated with a combination of intensive chemotherapy and prophylactic lung irradiation (PLI) intercalated between the first two cycles of chemotherapy. The primary tumor was treated according to its size and location by amputation, resection, high-dose radiotherapy, and salvage amputation for a tumor progressing under radiotherapy. Two weeks after surgery or simultaneously with radiotherapy, a three-drug regimen (cycle A) consisting of mitomycin C on day 1, vincristine followed by a 6-hour infusion of methotrexate on day 2 was given. Folinic acid rescue was started 6 hours after the end of the methotrexate infusion. A PLI of 20 G was given from day 10 to 22. On day 28, a four-drug regimen (cycle B) combining doxorubicin on day 1, vincristine on day 2 and dacarbazine with cyclophosphamide on days 3 to 6 was administered. Thereafter, five additional cycles of A and B were administered provided that the absolute number of polymorphonuclear cells and platelets had recovered. When these values were not attained, treatment was delayed until recovery. After a mean follow-up of 60.6 months, 16 patients have developed distant metastases, associated in four cases with local recurrence. Sixteen patients have died: 15 with metastases, one with no evidence of disease (toxic death). The overall survival of the entire group is 66% and the continuously disease-free survival 58% at 5 years. Alopecia, nausea, vomiting, asthenia, anorexia, and infraclinical and reversible impairment of lung ventilatory function were universal. A noticeable hematologic toxicity also was seen. One toxic death occurred after a pulmonary infection. Two patients developed cardiomyopathy. A multiparametic analysis of prognostic factors shows the very significant influence of age on treatment outcome. The continuous disease-free survival among the 17 patients younger than 15 years is 41% compared to 79% in older patients. The prognostic influence of age was independent of other factors. The delay (for more than two cycles) of methotrexate administration was the second independent prognostic factor. These results raise the question of using different protocols of adjuvant chemotherapy for patients younger or older than 15 years in order to optimize the curability/toxicity ratio. Citing Literature Volume61, Issue71 April 1988Pages 1304-1311 ReferencesRelatedInformation" @default.
• W4245709671 created "2022-05-12" @default.
• W4245709671 date "1988-04-01" @default.
• W4245709671 modified "2023-10-06" @default.
• W4245709671 title "Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation" @default.
• W4245709671 cites W1573156673 @default.
• W4245709671 cites W1970133810 @default.
• W4245709671 cites W1974907966 @default.
• W4245709671 cites W2046185046 @default.
• W4245709671 cites W2051183024 @default.
• W4245709671 cites W2052512461 @default.
• W4245709671 cites W2063759313 @default.
• W4245709671 cites W2080998316 @default.
• W4245709671 cites W2082675463 @default.
• W4245709671 cites W2239924772 @default.
• W4245709671 doi "https://doi.org/10.1002/1097-0142(19880401)61:7<1304::aid-cncr2820610705>3.0.co;2-i" @default.
• W4245709671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3125957" @default.
• W4245709671 hasPublicationYear "1988" @default.
• W4245709671 type Work @default.
• W4245709671 citedByCount "42" @default.
• W4245709671 countsByYear W42457096712012 @default.
• W4245709671 countsByYear W42457096712013 @default.
• W4245709671 countsByYear W42457096712014 @default.
• W4245709671 countsByYear W42457096712016 @default.
• W4245709671 countsByYear W42457096712019 @default.
• W4245709671 countsByYear W42457096712020 @default.
• W4245709671 countsByYear W42457096712022 @default.
• W4245709671 crossrefType "journal-article" @default.
• W4245709671 hasBestOaLocation W42457096711 @default.
• W4245709671 hasConcept C126322002 @default.
• W4245709671 hasConcept C141071460 @default.
• W4245709671 hasConcept C142724271 @default.
• W4245709671 hasConcept C143998085 @default.
• W4245709671 hasConcept C2776204877 @default.
• W4245709671 hasConcept C2776694085 @default.
• W4245709671 hasConcept C2776755627 @default.
• W4245709671 hasConcept C2777760704 @default.
• W4245709671 hasConcept C2778336483 @default.
• W4245709671 hasConcept C2779429289 @default.
• W4245709671 hasConcept C2779804826 @default.
• W4245709671 hasConcept C2780456651 @default.
• W4245709671 hasConcept C2781059491 @default.
• W4245709671 hasConcept C2781413609 @default.
• W4245709671 hasConcept C509974204 @default.
• W4245709671 hasConcept C71924100 @default.
• W4245709671 hasConceptScore W4245709671C126322002 @default.
• W4245709671 hasConceptScore W4245709671C141071460 @default.
• W4245709671 hasConceptScore W4245709671C142724271 @default.
• W4245709671 hasConceptScore W4245709671C143998085 @default.
• W4245709671 hasConceptScore W4245709671C2776204877 @default.
• W4245709671 hasConceptScore W4245709671C2776694085 @default.
• W4245709671 hasConceptScore W4245709671C2776755627 @default.
• W4245709671 hasConceptScore W4245709671C2777760704 @default.
• W4245709671 hasConceptScore W4245709671C2778336483 @default.
• W4245709671 hasConceptScore W4245709671C2779429289 @default.
• W4245709671 hasConceptScore W4245709671C2779804826 @default.
• W4245709671 hasConceptScore W4245709671C2780456651 @default.
• W4245709671 hasConceptScore W4245709671C2781059491 @default.
• W4245709671 hasConceptScore W4245709671C2781413609 @default.
• W4245709671 hasConceptScore W4245709671C509974204 @default.
• W4245709671 hasConceptScore W4245709671C71924100 @default.
• W4245709671 hasIssue "7" @default.
• W4245709671 hasLocation W42457096711 @default.
• W4245709671 hasLocation W42457096712 @default.
• W4245709671 hasOpenAccess W4245709671 @default.
• W4245709671 hasPrimaryLocation W42457096711 @default.
• W4245709671 hasRelatedWork W1953895440 @default.
• W4245709671 hasRelatedWork W1979187129 @default.
• W4245709671 hasRelatedWork W2066636228 @default.
• W4245709671 hasRelatedWork W2116042827 @default.
• W4245709671 hasRelatedWork W2255756343 @default.
• W4245709671 hasRelatedWork W2333858494 @default.
• W4245709671 hasRelatedWork W2376645157 @default.
• W4245709671 hasRelatedWork W2377772771 @default.
• W4245709671 hasRelatedWork W2418294778 @default.
• W4245709671 hasRelatedWork W2978216802 @default.
• W4245709671 hasVolume "61" @default.
• W4245709671 isParatext "false" @default.
• W4245709671 isRetracted "false" @default.
• W4245709671 workType "article" @default.